infecti
risk
clinic
xenotransplant
unknown
base
experi
human
allotransplant
assum
potenti
exist
transmiss
infect
viabl
cell
tissu
xenograft
risk
amplifi
concern
regard
uniqu
potenti
risk
transmiss
zoonot
infecti
agent
anim
swine
origin
human
recipi
diagnost
tool
exist
behavior
unpredict
immunosuppress
human
graft
recipi
term
xenosi
direct
zoonosi
xenozoonosi
use
suggest
potenti
emerg
novel
pathogen
xenotransplant
basic
research
result
seri
import
observ
includ
molecular
clone
porcin
endogen
retrovirus
perv
perv
receptor
identif
pervac
potenti
infect
human
cell
vitro
molecular
diagnost
tool
develop
pigderiv
pathogen
compar
affect
human
allograft
recipi
includ
porcin
cytomegaloviru
pcmv
porcin
lymphotrop
herpesviru
porcin
circovirus
hepat
e
viru
assay
also
exist
common
pathogen
virus
eg
adenoviru
parvoviru
encephalomyocard
viru
porcin
reproduct
respiratori
syndrom
viru
aujeski
diseas
enteroviru
b
bacteria
salmonella
leptospira
yersinia
speci
mycoplasma
hyopneumonia
parasit
cryptosporidium
isospora
speci
affect
swine
pigtoprim
xenotransplant
addit
diagnost
tool
develop
primat
baboon
macaqu
cmv
herpesvirus
given
intens
immunosuppress
requir
sustain
xenograft
function
nonhuman
primat
us
food
drug
administr
world
health
organ
nation
author
issu
guidanc
document
relat
xenotransplant
experi
allow
develop
consensu
guidelin
auspic
world
health
organ
regard
assess
donor
anim
human
recipi
porcin
xenograft
prevent
infecti
transmiss
event
despit
impress
progress
actual
risk
diseas
transmiss
xenotransplant
remain
unknown
earli
clinic
data
period
prior
optim
assay
develop
suggest
transmiss
event
uncommon
might
unrecogniz
among
expect
infect
occur
immunocompromis
transplant
recipi
howev
signific
progress
made
microbiolog
xenotransplant
notabl
screen
sourc
anim
clinic
trial
xenotransplant
observ
exemplifi
report
wynyard
et
al
microbiolog
safeti
first
clinic
pig
islet
xenotransplant
trial
new
zealand
report
new
zealand
governmentapprov
clinic
trial
alginateencapsul
porcin
islet
cell
transplant
fourteen
patient
suffer
hypoglycem
unawar
patient
receiv
islet
equival
singl
dose
auckland
island
strain
donor
pig
number
compon
trial
merit
comment
advanc
trial
pig
islet
prepar
test
microorgan
virus
bacteri
speci
one
protozoan
use
molecular
immunolog
assay
recipi
found
neg
test
perv
microorgan
multipl
time
point
yr
follow
transplant
note
coloni
donor
swine
deriv
herd
auckland
island
isol
sinc
biosecur
facil
data
support
safeti
trial
use
donor
anim
data
quit
encourag
field
predict
safeti
subsequ
trial
use
whole
vascular
organ
much
larger
cell
mass
donor
herd
approach
develop
assur
safeti
clinic
xenotransplant
provid
much
framework
prevent
donorderiv
infect
human
allotransplant
set
absolut
prevent
transmiss
infect
transplant
imposs
goal
would
make
lifesav
transplant
unavail
human
allotransplant
outbreak
diseas
eg
sar
coronaviru
west
nile
viru
local
epidemiolog
chaga
diseas
endem
fungi
affect
organ
donor
disproportion
affect
immunosuppress
allograft
recipi
donor
screen
potenti
pathogen
imposs
clinic
xenotransplant
level
safeti
develop
beyond
avail
human
organ
donor
given
avail
close
herd
donor
swine
routin
test
batteri
potenti
human
pathogen
microbiolog
assay
standard
profici
laboratori
valid
expert
refer
laboratori
xenotransplant
recipi
surveil
program
mandat
detect
known
previous
unknown
unexpect
pathogen
even
absenc
infecti
syndrom
futur
may
incorpor
new
technolog
eg
broadrang
primer
highthroughput
sequenc
nucleic
acid
look
unknown
pathogen
new
technolog
appli
xenotransplant
safeti
allotransplant
may
also
enhanc
